Takeda Pharmaceutical will invest approximately 100 billion yen (¥) to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. 

The new state-of-the-art facility will be the largest of its kind in the country and is expected to be operational by around 2030. The new site increases the capacity of Takeda’s current plasma manufacturing site in Narita, Japan almost five-fold and will enable Takeda to serve more patients in Japan sustainably, as well as add incremental capacity to its global manufacturing network.

The facility will be built to the highest global manufacturing standards, including the latest automation and advanced digital technologies. It will be a fully integrated plant, comprising of teardown, fractionation, purification, filling, finishing capabilities as well as a cold storage warehouse.

The design will be environmentally friendly to support Takeda's goal of achieving net-zero greenhouse gas emissions related to operations including scopes 1 and 2 before 2035. Takeda’s existing Narita plasma manufacturing site will continue day-to-day operations until at least the end of the decade, with continued necessary investments for maintenance.

The demand for PDTs has grown significantly over the last 20 years as diagnoses of rare diseases and earlier treatment of complex chronic diseases have improved. Patient need for PDTs in Japan is expected to grow significantly in the coming years and Takeda plans to register up to five global products and new indications over the next five years in Japan, with discussions continuing with the authorities looking at ways to secure reliable supply and enable more patients to have continuity of care.